Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-04-24
2004-09-28
Stockton, Laura L. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S365000, C548S194000, C548S125000, C548S127000, C548S134000, C548S136000, C548S236000, C548S214000, C548S376100, C548S247000, C548S562000, C548S572000, C548S377100, C549S066000, C549S501000
Reexamination Certificate
active
06797723
ABSTRACT:
BACKGROUND OF THE INVENTION
The metabolic routes in which various compounds are biosynthesized from arachidbnic acid, are collectively called the “Arachidonic Acid Cascade.”
Leukotriene B
4
(LTB
4
) is one of many products resulting from the arachidonic acid cascade.
Moreover, LTB
4
in high concentration has been detected at the sites of various inflammatory conditions, for example, rheumatism, spinal arthritis (see Klickstein L. B., Shapleigh, C. and Goetzl, E. J. (1980) J. Clin. Invest., 66, 1166-1170), gout (Rae, S. A., Davidson, E. M. and Smith, M. J. H. (1982) Lancet II 1122-1123), psoriasis (see Grabbe, J., Czarnetzki, B. M., Rosenbach, T. and Mardin, M. (1984) J. Invest. Dermatol., 82, 477-479), ulcerative colitis (see Sharon, P. and Stenson, W. F. (1984) Gastroenterology 86, 453-460). and respiratory disease (see O'Driscoll, B. R., Cromwell, O. and Kay, A. B. (1984) Clin. Exp., Immunol., 55, 397-404). The facts described above show that LTB
4
is deeply related to various forms of inflammation. It has been suggested that compounds antagonizing LTB
4
activity may be valuable in the treatment of inflammatory diseases caused by tissue degrading enzymes and reactive chemicals liberated by tissue-infiltrating and aggregating polymorphonuclear leukocytes.
For example, PCT Japanese National Publication No. 6-502164 describes novel monocylic or bicyclic aryl compounds are selectively antagonistic to LTB
4
and are useful for treatment of rheumatoid arthritis, gout, psoriasis and inflammatory bowel disease. Japanese Unexamined Patent Publication (Kokai) No. 4-244023 describes that omega 6 series unsaturated fatty acids such as &ggr;-linolenic acid are useful for treatment of arrhythmia, acute myocardial infarction etc, by inhibiting production of LTB
4
. Japanese Unexamined Patent Publication No. 5-310668 describes that a novel leucine derivative has an inhibitory action to LTA
4
hydrolase and is useful for treatment and prophylaxis of allergic diseases such as bronchial asthma, various inflammatory diseases, and ischemia-reperfusion disorders. Japanese Unexamined Patent Publication (Kokai) No. 1-190656 discloses that novel leukotriene B
3
dimethyl amide has an antagonistic action to LTB
4
and is useful as anti-inflammatory drug, anti-rheumatic drug and gout-treatment drug.
The article, “Second Generation Leukotriene B4 Receptor Antagonists Related to SC-41930: Heterocyclic Replacement of the Methyl Ketone Pharmacophore”, J. Med Chem, 1995, 38, p.858-868 by Penning, Thomas D. et. al.; describes heterocycle substituted LTB
4
antagonists.
Pyrazole LTB
4
antagonists are disclosed in the article, “Leukotriene B4 (LUB
4
) Receptor Antagonists: A Series of (Hydroxyphenyl)pyrazoles” by Richard W. Harper, et. al.,
J. Med Chem,
1994, 37, pgs. 2411-2420.
Leukotriene B
4
antagonists, inclusive of diphenyl ethers such as 2-[2-propyl-3-[3-[2-ethyl-5-hydroxy-4-(4-fluorophenyl)phenoxylpropoxy]phenoxy]benzoic acid, are described in U.S. Pat. No. 5,462,954, the disclosure of which is incorporated herein by reference. The same type of leukotriene B
4
antagonists are described in the article, “Synthetic and Structure/Activity Studies on Acid-Substituted 2-Arylphenols: Discovery of 2-[2-Propyl-3-(3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]-propoxy]phenoxy]benzoic Acid, a High-Affinity Leukotriene B
4
Receptor Antagonist” by J. Scott Sawyer, et. al.,
Journal of Medicinal Chemistry,
1995, 38, pgs. 4411-4432.
These diphenyl ether leukotriene B
4
antagonists, in combination with a 2′,2′-difluoronucleoside analog (e.g., GEMCITABINE HCl, have also been found to have utility in the treatment of various cancers, as further described in Provisional Patent Application Serial No. 60/164786, filed 11 Nov. 1999, the disclosure of which is incorporated herein by reference.
Currently, anti-inflammatory drugs are classified as steroidal and non-steroidal. Although these drugs provide anti-inflammatory action they all have drawbacks which limit their use. A more recent approach to the moderation of inflammation focuses on blocking the action of arachidonic acid metabolites.
Leukotriene B
4
antagonists are useful for a wide variety of Inflammatory Diseases, but it is expected that various of these antagonists will show superior results with particular disease states. This is one reason it is desirable to develop new leukotriene B
4
antagonists such as the compounds of this invention.
SUMMARY OF THE INVENTION
The present invention is directed to novel heterocycle substituted diphenyl compounds of formula (I)
Another aspect of this invention are pharmaceutical compositions containing the compounds of formula (I).
Another aspect of this invention is a method of using the compounds of the invention in the prevention and treatment of LTB
4
induced illnesses.
Another aspect of this invention is a compound of formula (I) for use as a medicament in the treatment or prevention of Inflammatory Diseases.
Another aspect of this invention is a process for preparing a compound of Formula (I).
REFERENCES:
patent: 5462954 (1995-10-01), Baker et al.
patent: 5543428 (1996-08-01), Sawyer et al.
patent: 5910505 (1999-06-01), Fleisch et al.
patent: 6071949 (2000-06-01), Mulshine et al.
patent: 544488 (1998-03-01), None
patent: WO 01/34137 (2001-05-01), None
patent: WO 01/34580 (2001-05-01), None
patent: WO 01/85166 (2001-11-01), None
“Synthetic and Structure /Activity Studies on Acid-Substituted 2-Arylphenols” by J. Scott Sawyer, et al., Journal of Medicial Chemistry, 1995, 38 pp. 4411-4432.
“Second Generation Leukotriene B4 Receptor Antagonists Related to SC-41930” by Penning, Thomas D. et al., J. Med. Chem., 1995, 38, pp. 858-868.
“Leukotriene B4 (LTB4) Receptor Antagonists” by Harper, Richard W. et. al., J. Med. Chem., 1994, 37, pp. 2411-2420.
Beight Douglas Wade
McMillen William Thomas
Sawyer Jason Scott
Smith Edward C R
Benjamin Roger S.
Eli Lilly and Company
Stockton Laura L.
LandOfFree
Heterocycle substituted diphenyl leukotriene antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocycle substituted diphenyl leukotriene antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocycle substituted diphenyl leukotriene antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3217271